Post-transplant cyclophosphamide (PTCy) is increasingly used for graft-versus-host disease (GVHD) prophylaxis in both HLA-matched (matched-PTCy) and haplotype-mismatched (haplo-PTCy) hematopoietic stem cell transplantation (HCT), but the effects of PTCy on immune reconstitution in different donor settings remain incomp...
Michela Ansuinelli, H. Kim, Francesco Malfona et al.· Blood Advances· 0 citations
The interplay between the repertoire of antigens presented by the tumor and the breadth of induced immunity seemed to dictate clinical efficacy following vaccination, and this was associated with broader tumor and vaccine-specific immune responses in blood and tumor following vaccination.
Maclean C. Sellars, Jessica A. Frank, Bohoon Shim et al.· Nature Medicine· 0 citations
Solid tumors evade immunotherapy because of immunosuppressive microenvironments that limit immune cell persistence and function. Although interleukin-12 (IL-12) potently activates antitumor immunity, its clinical use has been constrained by systemic toxicity. Here we engineered a CAR natural killer (NK) cell platform t...
Mubin Tarannum, K. Dinh, Mila Stanojevic et al.· Cancer Discovery· 0 citations
Tertiary lymphoid structures are reservoirs of tumour-specific T cells with stem-like progenitor features that could be leveraged by T cell immunotherapies, and are found to be reservoirs of tumour-specific T cells with stem-like progenitor features that could be leveraged by T cell immune pressure.
Alexander B. Afeyan, Adi Nagler, Chloe R. Tu et al.· Nature· 2 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.